Hepatocellular Carcinoma Clinical Trials in Chicago, Illinois

4 studies are recruiting for hepatocellular carcinoma in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma

    This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in pa…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Research Site, Chicago, Illinois
    Locations
    219 in total
    Run by
    AstraZeneca

    See if you can join NCT06921785 on ClinicalTrials.gov

  2. Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Northwestern University Feinberg School of Medicine /ID# 257378, Chicago, Illinois
    Locations
    54 in total
    Run by
    AbbVie

    See if you can join NCT06084481 on ClinicalTrials.gov

  3. Therasphere® and Systemic Therapy for Patients With Hepatocellular Carcinoma That is High-risk

    The purpose of this research is to compare progression free survival between two available systemic therapies - immunotherapy and tyrosine kinase inhibitors - after Therasphere® (yttrium-90) treatment in adult patients with advanced hepatocellular carcinoma. The immunotherapy consists of a standard…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    Northwestern University, Chicago, Illinois
    Locations
    7 in total
    Run by
    Northwestern University

    See if you can join NCT05620771 on ClinicalTrials.gov

  4. A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

    Hepatocellular carcinoma (HCC) is a common cancer worldwide and a leading cause of cancer-related death. The majority of participants first presenting with HCC have advanced unresectable or metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    The University of Chicago Medical Center /ID# 255674, Chicago, Illinois
    Locations
    37 in total
    Run by
    AbbVie

    See if you can join NCT06109272 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.